If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The number of events at the park grew significantly after its reopening, causing some consternation by people who feared that the park would be dominated by private entities, thus would be inaccessible to the public. As a result, BPC makes most events free and open to the public. One exception was the New York Fashion Week shows that formerly took over the park for two weeks in the winter and late summer each year. BPC cofounder Dan Biederman often publicly expressed his frustration that the fashion shows were not under BPC's control. "They pay us a million dollars. It's a million dollars I would happily do without," he told the Los Angeles Times. BPC was particularly frustrated that the fashion shows dominated the park during two crucial times: in late summer, when the weather is perfect for park visitors; and in early February, necessitating the early closure of the park's popular free-admission ice-skating rink.
== Biography == Palmer was born in Port of Spain on the twin island Republic of Trinidad and Tobago. He is fluent in English and became a U.S. citizen. Palmer earned a chemical engineering degree at Howard University in Washington D.C in 1993 and his doctorate in chemical and biomolecular engineering at Johns Hopkins University in 1998. After completing postdoctoral work at Johns Hopkins University in 1999, Palmer joined the Chemistry Department faculty at Howard University. In 2001, he left for the University of Notre Dame to become assistant professor of chemical and biomolecular engineering. In 2006, after five years, he moved to Ohio State University to become associate professor of chemical and biomolecular engineering, and was promoted to full professor in 2012. He served as interim department chair in 2014–2015. In 2015, he was named Chair of the William G. Lowrie Department of Chemical and Biomolecular Engineering and served until 2019. In March 2020, the Ohio Board of Regents named Palmer, "Ohio Eminent Scholar," a statewide endowed chair. In August 2021, Palmer was appointed Associate Dean for research, charged with directing the College of Engineering's $138 million research enterprise.
== Overview == The MCSGP process consists of several, at least two, chromatographic columns which are switched in position opposite to the flow direction. Most of the columns are equipped with a gradient pump to adjust the modifier concentration at the column inlet. Some columns are connected directly, so that non pure product streams are internally recycled. Other columns are short circuited, so that they operate in pure batch mode. The system is split into several sections, from which every section performs a tasks analogous to the tasks of a batch purification. These tasks are loading the feed, running the gradient elution, recycling of weakly adsorbing site fractions, fractionation of the purified product, recycling of strongly adsorbing site fractions, cleaning the column from strongly adsorbing impurities, cleaning in place and re-equilibration of the column to start the next purification run. All of the tasks mentioned here are carried out at the same time in one unit. Recycling of non-pure side fractions is performed in countercurrent movement.
=== Protein radical formation === Glycyl radical enzyme activating enzymes (GRE-AEs) are radical SAM subset that can house a stable and catalytically essential glycyl radical in their active state. The underlying chemistry is considered to be the simplest in the radical SAM superfamily with H-atom abstraction by the 5'-dAdo radical being the product of the reaction. A few examples include:
==== Detecting trojans ==== Machine learning models can potentially contain "trojans" or "backdoors": vulnerabilities that bad actors maliciously build into an AI system. For example, a trojaned facial recognition system could grant access when a specific piece of jewelry is in view; or a trojaned autonomous vehicle may function normally until a specific trigger is visible. This might not be difficult to do with some large models like CLIP or GPT-3 as they are trained on publicly available internet data. Researchers were able to plant a trojan in an image classifier by changing just 300 out of 3 million of the training images. In addition to posing a security risk, researchers have argued that trojans provide a concrete setting for testing and developing better monitoring tools. A 2024 research paper by Anthropic showed that large language models could be trained with persistent backdoors. These "sleeper agent" models could be programmed to generate malicious outputs (such as vulnerable code) after a specific date, while behaving normally beforehand. Standard AI safety measures, such as supervised fine-tuning, reinforcement learning and adversarial training, failed to remove these backdoors.
Sources: en.wikipedia.org
=== Disadvantage === As some proteins require chaperonin for proper folding, Komagataella is unable to produce a number of proteins, since it does not contain the appropriate chaperones. The technologies of introducing genes of mammalian chaperonins into the yeast genome and overexpressing existing chaperonins still require improvement.
When lipids are extracted or isolated from biomembranes, polymorphism and mesomorphism can occur because they are then no longer under the intermolecular constraints that are present within the biomembrane. This can lead to formation of non-lamellar (non-bilayer) or lamellar phases in phospholipids. "Polymorphism" refers to formation of diverse structures such as three-dimensional tubes, rods, and structures with cubic symmetry. Mesomorphism refers to phase transitions when heat is applied. For example, a lipid can be in the lamellar phase at a lower temperature, but as the temperature increases, it transitions into a non-lamellar phase. It is important to consider the size of the hydrophilic region versus the hydrophobic region. For example, if the hydrophilic region and hydrophobic region are similar, a cylindrical shape lipid bilayer is formed; but when the hydrophilic regions is smaller than the hydrophobic region a cone-shaped lipid bilayer is formed. Another example is the formation of micelles which has a non-lamellar formation in which the hydrophilic region is significantly larger compared to the hydrophobic region. There are various liquid-crystalline phases that can exist in lipids. Liquid-crystalline phases are when the hydrophobic chain regions are not motionless but are allowed to move about freely in a fluid-like melted state. The lamellar phase (Lα) is the most common and dominant phase in lipids and are aligned as stacks of bilayers on top of bilayers oriented in one single direction.
== Formylation reactions in biology == In biochemistry, the addition of a formyl functional group is termed "formylation". A formyl functional group consists of a carbonyl bonded to hydrogen. When attached to an R group, a formyl group is called an aldehyde. Formylation has been identified in several critical biological processes. Methionine was first discovered to be formylated in E. coli by Marcker and Sanger in 1964 and was later identified to be involved in the initiation of protein synthesis in bacteria and organelles. The formation of N-formylmethionine is catalyzed by the enzyme methionyl-tRNAMet transformylase. Additionally, two formylation reactions occur in the de novo biosynthesis of purines. These reactions are catalyzed by the enzymes glycinamide ribonucleotide (GAR) transformylase and 5-aminoimidazole-4-carboxyamide ribotide (AICAR) transformylase. More recently, formylation has been discovered to be a histone modification, which may modulate gene expression.
=== Reelection and Second Term (2024–present) === Melo was reelected in 2024 by a wide margin, obtaining 61.53% in the second round. He defeated his second-place rival, Maria do Rosário, who had obtained 38.47% of the vote.
It is an optical analytical technique that analyzes the interference pattern of white light reflected from two surfaces: a layer of immobilized protein on the biosensor tip, and an internal reference layer. Any change in the number of molecules bound to the biosensor tip causes a shift in the interference pattern that can be measured in real-time, providing detailed information regarding the kinetics of association and dissociation of the two molecules as well as the affinity constant for the protein interaction (ka, kd and Kd). Due to sensor configuration, the technique is highly amenable to both purified and crude samples as well as high throughput screening experiments. The detection method can also be used to determine the molar concentration of analytes. Protein activity determination by NMR multi-nuclear relaxation measurements, or 2D-FT NMR spectroscopy in solutions, combined with nonlinear regression analysis of NMR relaxation or 2D-FT spectroscopy data sets. Whereas the concept of water activity is widely known and utilized in the applied biosciences, its complement—the protein activity which quantitates protein–protein interactions—is much less familiar to bioscientists as it is more difficult to determine in dilute solutions of proteins; protein activity is also much harder to determine for concentrated protein solutions when protein aggregation, not merely transient protein association, is often the dominant process.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.